Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
174 hedge funds and large institutions have $1.01B invested in Acorda Therapeutics in 2018 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 53 increasing their positions, 53 reducing their positions, and 24 closing their positions.
144% more call options, than puts
Call options by funds: $43.9M | Put options by funds: $18M
0% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 24
0% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 53
1% less funds holding
Funds holding: 175 → 174 (-1)
29% less capital invested
Capital invested by funds: $1.42B → $1.01B (-$408M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| 1 |
State Street
Boston,
Massachusetts
|
+$21M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$18.7M |
| 3 |
Renaissance Technologies
New York
|
+$15.3M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$14.5M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14.1M |
Top Sellers
| 1 |
BlackRock
New York
|
-$26.4M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$23.6M |
| 3 |
SCM
Scopia Capital Management
New York
|
-$13.7M |
| 4 |
Two Sigma Investments
New York
|
-$5.07M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
-$4.97M |
ACOR Hedge Fund Activity: Q3 2018 in Review
174 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q3 2018, worth a combined $1.01B — down 29% from $1.42B a quarter earlier.
Fund positioning in ACOR was balanced in Q3 2018: 24 funds opened new positions, 24 closed out, 53 added to existing stakes and 53 trimmed.
The largest buyer was State Street, adding an estimated $21M. The largest seller was BlackRock, cutting an estimated $26.4M.
- 174 institutional investors held Acorda Therapeutics (ACOR) as of Q3 2018, down from 175 in Q2 2018.
- Funds reported $1.01B of Acorda Therapeutics stock for Q3 2018, down 29% quarter-over-quarter.
- 24 funds opened new Acorda Therapeutics positions in Q3 2018 and 24 closed out, a net change of 0 holders.
- The largest Acorda Therapeutics buyer in Q3 2018 was State Street, an estimated $21M added.
- The largest Acorda Therapeutics seller in Q3 2018 was BlackRock, an estimated $26.4M sold.
Based on aggregated 13F filings for Q3 2018.